IGF-1 Analogues: LR3 and DES Structural Variations and Receptor Binding in Research Models
Introduction Insulinlike Growth Factor1 (IGF1) is a central mediator of growth hormone (GH) signaling involved in tissue growth, cellular repair, metabolic function, and proliferation. Two widely examined analogues—IGF1 LR3 and IGF1 DES—help researchers study how structural modifications influence receptor activation, signaling duration, and tissuespecific responses. This article outlines IGF1 biology followed by detailed sections on LR3 and DES, written strictly from a mechanistic, researchbased perspective. What Is IGF 1? IGF1 is a peptide hormone produced primarily in the liver in response to GH stimulation. It activates IGF1 receptors (IGF1R) and, to a lesser extent, insulin receptors (IR). Its downstream effects operate through the PI3K–AKT, MAPK, and mTOR pathways, influencing metabolism, survival, and growth. Because native IGF1 is regulated by IGF binding proteins (IGFBPs), analogues offer a controlled way to study IGF1Rspecific activity. LR3 IGF1: Structural Modification and Extended Activity IGF1 LR3 features a 13aminoacid Nterminal extension and a substitution of arginine at position 3. These modifications significantly reduce IGFBP binding, increasing receptor availability and extending activity. In research settings, LR3 allows longduration IGF1R stimulation and activation of PI3KAKT, MAPK, and mTOR pathways under reduced IGFBP interference. IGF1 DES (1–3 IGF1): Truncated Analogue With Enhanced Local Activity IGF1 DES lacks the first three amino acids of the IGF1 sequence, further decreasing IGFBP binding. This analogue produces rapid and localized IGF1R activation with a shorter activity period. Its strong local receptor affinity makes DES useful for studying tissuespecific IGF1 effects and acute signaling responses. Mechanistic Comparison LR3 and DES share the same receptor target (IGF1R) but differ in duration, IGFBP interaction, and tissue penetration. LR3 provides sustained receptor access and broad exposure, while DES offers intense, localized IGF1R activation for shorter intervals. Both contribute complementary insights into IGF1’s biological roles in controlled research environments. IGF1R Signaling Overview IGF1R engagement activates multiple intracellular pathways: PI3K → AKT (survival, glucose metabolism) RAS → MAPK (growth, differentiation) mTOR (protein synthesis, anabolic signaling) IRS1/2 (insulin/IGF crosstalk) These pathways underpin IGF1’s metabolic and growthregulating effects in research models. Summary IGF‑1 analogues such as LR3 and DES help researchers examine how structural modifications influence receptor engagement, signaling intensity, and tissue specificity. LR3 provides sustained IGF‑1R signaling due to reduced IGFBP interaction, while DES offers rapid, localized receptor activation with a shorter halflife. Together, the analogues support comprehensive study of IGF‑1 pathway biology under different experimental designs. LR3 vs DES: Mechanistic Comparison (Research Only) | Parameter | IGF1 LR3 | IGF1 DES | | | | | | Structure | 13aa extension + Arg3 substitution | Truncated by 3 amino acids | | IGFBP Interaction | Reduced | Strongly reduced | | Receptor Activation | Sustained IGF1R exposure | Rapid, localized IGF1R activation | | Research Focus | Extended signaling duration | Shortduration, highintensity signaling | | HalfLife | Longer activity window | Shorter activity window | Educational & Research Disclaimer This article is for educational and research purposes only. No medical advice or product claims are made. These compounds are not approved for human use and are intended solely for laboratory research. FAQ: What are IGF1 LR3 and IGF1 DES in research? IGF1 LR3 and IGF1 DES are synthetic analogues of the native growthfactor peptide Insulin‑like Growth Factor 1 (IGF1). LR3 includes added amino acids and a substitution to reduce binding to IGFbinding proteins, while DES is a truncated form (missing the first three amino acids). Both are studied for their modified receptorbinding profiles, bioavailability, and signaling activity in experimental models. How do IGF1 LR3 and IGF1 DES function in laboratory studies? Research shows that LR3 has reduced affinity for IGFbinding proteins (IGFBPs) and a longer halflife, allowing increased receptor interaction and signaling effects compared to native IGF1. Similarly, DES(13)IGF1 lacks the first three amino acids, exhibits markedly reduced IGFBP binding and enhanced potency in specific systems. Are IGF1 LR3 and IGF1 DES considered therapeutic products? No. The versions described here are for research use only by The Peptide Company. They are not approved therapies, supplements, or consumer products and are intended for controlled laboratory and invitro experimentation only. What research applications involve IGF1 LR3 and IGF1 DES? These analogues are used in experimental studies investigating tissuespecific growthfactor effects, receptorbinding kinetics, bioavailability outside IGFBP regulation, metabolic and endocrine signa
For research use only. Not for human consumption.